BRIEF-J&J Says Phase 3 Iconic-Advance 1&2 Studies Met Their Co-Primary Endpoints

Reuters
08 Mar
BRIEF-J&J Says Phase 3 Iconic-Advance 1&2 Studies Met Their Co-Primary Endpoints

March 8 (Reuters) - Johnson & Johnson JNJ.N:

  • J&J - ICOTROKINRA RESULTS SHOW POTENTIAL TO SET A NEW STANDARD OF TREATMENT IN PLAQUE PSORIASIS

  • J&J - PHASE 3 ICONIC-ADVANCE 1&2(E )STUDIES MET THEIR CO-PRIMARY ENDPOINTS

Source text: ID:nPnbrgc7fa

Further company coverage: JNJ.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10